Taienkang: Voluntary Disclosure Notice on the Progress of Clinical Trials of the Class 1 Innovative Drug CKBA Ointment developed by the holding subsidiary

SZSI · Oct 31

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.